Literature DB >> 23402640

A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in papillary thyroid carcinoma after total thyroidectomy.

Brian Hung-Hin Lang1, Sze-How Ng, Lincoln L H Lau, Benjamin J Cowling, Kai Pun Wong, Koon Yat Wan.   

Abstract

BACKGROUND: Prophylactic central neck dissection (pCND) at the time of total thyroidectomy (TT) remains controversial in clinically node-negative (cN0) papillary thyroid carcinoma (PTC). Despite occult central lymph node metastases being common, it is unclear if removing these metastases initially would reduce future locoregional recurrence (LRR). This systematic review and meta-analysis aimed at comparing the short-term LRR between patients who underwent TT with pCND and those who underwent TT alone.
METHODS: A systematic review of the literature was performed to identify studies comparing LRR between patients with PTC who underwent TT + pCND (group A) and those who underwent TT alone (group B). Inclusion criteria were cN0 patients, with each comparative group containing > 10 patients, and with the number of LRR and mean follow-up duration available. The pooled incidence rate ratio (IRR) was used for calculating the LRR rate between the two groups. Other parameters evaluated included postoperative radioiodine (RAI) ablation, surgically related complications, and overall morbidity. Meta-analysis was performed using a fixed-effects model.
RESULTS: Fourteen studies matched the selection criteria. Of the 3331 patients, 1592 (47.8%) belonged to group A, while 1739 (52.2%) belonged to group B. Relative to group B, group A was significantly more likely to have postoperative RAI ablation (71.7% vs. 53.1%; odds ratio [OR] = 2.60 [95% confidence interval (CI) = 2.12-3.18]), temporary hypocalcemia (26.0% vs. 10.8%; OR = 2.56 [CI = 2.04-3.21]), and overall morbidity (33.2% vs. 17.7%; OR = 2.12 [CI = 1.75-2.57]). When temporary hypocalcemia was excluded, overall morbidity was similar between the two groups (7.3% vs. 6.8%; OR = 1.07 [CI = 0.78-1.47]). Group A had a significantly lower risk of LRR than group B (4.7% vs. 8.6%; IRR = 0.65 [CI = 0.48-0.86]).
CONCLUSIONS: Group A was more likely to have postoperative RAI ablation, temporary hypocalcemia, and overall morbidity than group B. Temporary hypocalcemia was the major surgical morbidity in pCND and, when excluded, the overall morbidity appeared similar between the two groups. Although our meta-analysis would suggest that those who undergo TT + pCND may have a 35% reduction in risk of LRR than those who undergo TT alone in the short term (< 5 years), it remains unclear how much of this risk reduction is related to increased use of RAI ablation and potential selection bias in some of the studies examined.

Entities:  

Mesh:

Year:  2013        PMID: 23402640     DOI: 10.1089/thy.2012.0608

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  60 in total

1.  Quantification of lymph nodes in the central compartment of the neck: a cadaveric study.

Authors:  Enyinnaya Ofo; Selvam Thavaraj; Daron Cope; James Barr; Karan Kapoor; Jean-Pierre Jeannon; Richard Oakley; Claire Lock; Edward Odell; Ricard Simo
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-11-20       Impact factor: 2.503

Review 2.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

Review 3.  Prophylactic central neck disection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Juan J Sancho; Thomas W Jay Lennard; Ivan Paunovic; Frédéric Triponez; Antonio Sitges-Serra
Journal:  Langenbecks Arch Surg       Date:  2013-12-19       Impact factor: 3.445

Review 4.  Impact of prophylactic central neck dissection on oncologic outcomes of papillary thyroid carcinoma: a review.

Authors:  Elisabeth Mamelle; Isabelle Borget; Sophie Leboulleux; Haïtham Mirghani; Carlos Suárez; Phillip K Pellitteri; Ashok R Shaha; Marc Hamoir; K Thomas Robbins; Avi Khafif; Juan P Rodrigo; Carl E Silver; Alessandra Rinaldo; Alfio Ferlito; Dana M Hartl
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-11       Impact factor: 2.503

5.  Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option.

Authors:  Jérôme Clerc; Frederik A Verburg; Anca M Avram; Luca Giovanella; Elif Hindié; David Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

Review 6.  Surgical approach to level VI in papillary thyroid carcinoma: an overview.

Authors:  Carmela De Crea; Marco Raffaelli; Luca Sessa; Celestino Pio Lombardi; Rocco Bellantone
Journal:  Updates Surg       Date:  2017-06-13

7.  Sentinel node biopsy in papillary thyroid cancer--what is the potential?

Authors:  S P Balasubramanian; J Brignall; H Y Lin; T J Stephenson; J Wadsley; B J Harrison; W L Craig; L Smart; Z Krukowski
Journal:  Langenbecks Arch Surg       Date:  2014-01-21       Impact factor: 3.445

8.  Incidence and predictors of post-thyroidectomy hypocalcaemia in a tertiary endocrine surgical unit.

Authors:  O Edafe; P Prasad; B J Harrison; S P Balasubramanian
Journal:  Ann R Coll Surg Engl       Date:  2014-04       Impact factor: 1.891

9.  Role of sentinel node in differentiated thyroid cancer: a prospective study comparing patent blue injection technique, lymphoscintigraphy and the combined technique.

Authors:  R Gelmini; M Campanelli; F Cabry; A Franceschetto; G Ceresini; L Ruffini; A Zaccaroni; P Del Rio
Journal:  J Endocrinol Invest       Date:  2017-08-31       Impact factor: 4.256

10.  Does preoperative neutrophil lymphocyte ratio predict risk of recurrence and occult central nodal metastasis in papillary thyroid carcinoma?

Authors:  Brian Hung-Hin Lang; Cathy Po-Ching Ng; Kin Bun Au; Kai Pun Wong; Kandy K C Wong; Koon Yat Wan
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.